Health
Study shows 90.7% efficacy for the BNT162b2 COVID vaccine in 5-11 year-olds – News-Medical.Net
A new study evaluates the safety, immunogenicity, and efficacy of the BNT162b2 in children who were 5 to 11 years of age.
Vaccination against coronavirus disease 2019 (COVID-19) has been considered to be the most effective way to reduce the mortality and morbidity of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Several vaccine candidates have…
Continue Reading
-
General22 hours agoWondering about winter | The Spectator Australia
-
General20 hours agoParents of Heidi, 3, remember ‘beautiful’ daughter killed in Ocean Grove crash
-
Noosa News21 hours agoJane Bunn weather: Cyclone Errol forms as effects of Alfred still felt across Queensland
-
General21 hours agoNo ‘band-aid solution’: sweating coal risky business